Follow the 에스케이바이오팜 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 에스케이바이오팜 has recorded 33 reports. Market capitalisation: €5,904.8bn. The latest transaction was filed on 1 April 2026 (Sale). Among the most active insiders: 조형래. The full history is openly available.
33
Insider Decl.
n/a
Thresholds
n/a
7 ops.
Buy Volume
n/a
2 ops.
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,569 of 29,063 companies
67.3
score / 100
Value
41
Quality
93
FCF yld2.5%
Earn yld4.5%
EV/EBITDA33.9x
ROE44%
Gross mgn94%
Net mgn38%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
